Complex and Higher Risk Procedures for Indicated Patients (CHIP)
Prognostic Impact of CHA2DS2-VASc-HS Score on Midterm Clinical Outcomes after Elective PCI for Chronic Coronary Syndrome: A Single-center Retrospective Study
Tomoaki Ukaji1, Tetsuya Ishikawa1, Kota Yamada1, Yukiko Mizutani1, Hidehiko Nakamura1, Itaru Hisauchi1, Yuji Itabashi1, Shiro Nakahara1, Sayuki Kobayashi1, Isao Taguchi1
Dokkyo Medical University, Japan1
Weretrospectively examined the association of CHA2DS2-VASc-HS score on midtermclinical outcomes after elective PCI for chronic coronary syndrome (CCS),because the prognostic impact of CHA2DS2-VASc-HS score on the patients with CCSwas not fully understood in the present drug-eluting stent (DES) era.
Forthis purpose, consecutive 588 denovo coronary stenosis in 376 patients with CCSsuccessfully revascularized during from 2017 January to 2019 December wasdivided into two groups with CHA2DS2-VASc-HS score of 6 points: low (L: n=483)and high (H: n=105) groups. The primary clinical endpoint was the incidence oftarget lesion failure (TLF) comprising of cardiac death, non-fatal myocardialinfarction, and any target vessel revascularization.
Thefrequency of TLF in H group (21.0% with the mean observational interval of652±468 days) was significantly higher than that in L group (p<0.001).Cumulated TLF-free ratio of H group was significantly lower than that in Lgroup (p<0.001, by log-rank test). Multivariate Cox hazard proportionalanalysis showed that CHA2DS2-VASc-HS score <=6 was the single significantpredictor of TLF among 29 variables (Hazard ratio: 2.26, 95%CI: 1.30-3.93,p=0.004).
Thus,the present retrospective single center analysis showed the significantprognostic impact of CHA2DS2-VASc-HS score on the incidence of midterm clinicaloutcomes after elective PCI for patients with CCS.